首页> 美国卫生研究院文献>ILAR Journal >Mouse Models for Drug Discovery. Can New Tools and Technology Improve Translational Power?
【2h】

Mouse Models for Drug Discovery. Can New Tools and Technology Improve Translational Power?

机译:用于药物发现的鼠标模型。新工具和新技术能否提高翻译能力?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The use of mouse models in biomedical research and preclinical drug evaluation is on the rise. The advent of new molecular genome-altering technologies such as CRISPR/Cas9 allows for genetic mutations to be introduced into the germ line of a mouse faster and less expensively than previous methods. In addition, the rapid progress in the development and use of somatic transgenesis using viral vectors, as well as manipulations of gene expression with siRNAs and antisense oligonucleotides, allow for even greater exploration into genomics and systems biology. These technological advances come at a time when cost reductions in genome sequencing have led to the identification of pathogenic mutations in patient populations, providing unprecedented opportunities in the use of mice to model human disease. The ease of genetic engineering in mice also offers a potential paradigm shift in resource sharing and the speed by which models are made available in the public domain. Predictively, the knowledge alone that a model can be quickly remade will provide relief to resources encumbered by licensing and Material Transfer Agreements. For decades, mouse strains have provided an exquisite experimental tool to study the pathophysiology of the disease and assess therapeutic options in a genetically defined system. However, a major limitation of the mouse has been the limited genetic diversity associated with common laboratory mice. This has been overcome with the recent development of the Collaborative Cross and Diversity Outbred mice. These strains provide new tools capable of replicating genetic diversity to that approaching the diversity found in human populations. The Collaborative Cross and Diversity Outbred strains thus provide a means to observe and characterize toxicity or efficacy of new therapeutic drugs for a given population. The combination of traditional and contemporary mouse genome editing tools, along with the addition of genetic diversity in new modeling systems, are synergistic and serve to make the mouse a better model for biomedical research, enhancing the potential for preclinical drug discovery and personalized medicine.
机译:小鼠模型在生物医学研究和临床前药物评估中的使用正在增加。诸如CRISPR / Cas9之类的新的分子基因组改变技术的出现允许将基因突变比以前的方法更快,更便宜地引入小鼠的种系。此外,利用病毒载体进行体细胞转基因的开发和使用的快速进展,以及使用siRNA和反义寡核苷酸对基因表达进行的操纵,使得人们可以对基因组学和系统生物学进行更大的探索。这些技术进步之时正值基因组测序成本降低导致鉴定患者群体中的致病突变之时,为使用小鼠模拟人类疾病提供了前所未有的机会。小鼠基因工程的简便性还提供了资源共享的潜在范式转变,以及在公共领域提供模型的速度。可以预见的是,仅凭知识就可以快速重建模型,就可以减轻许可和材料转让协议所占用的资源。几十年来,小鼠品系提供了一种精美的实验工具来研究该疾病的病理生理学,并评估在遗传定义的系统中的治疗选择。但是,小鼠的主要局限性是与普通实验室小鼠相关的有限的遗传多样性。最近开发的交叉杂交和多样性杂种小鼠克服了这一问题。这些菌株提供了新的工具,能够将遗传多样性复制到接近人类种群的遗传多样性。因此,交叉杂交和多样性杂种协作菌株为特定人群提供了观察和表征新治疗药物的毒性或功效的方法。传统和现代鼠标基因组编辑工具的结合,以及新建模系统中遗传多样性的增加,具有协同作用,有助于使鼠标成为用于生物医学研究的更好模型,从而增强了临床前药物发现和个性化医学的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号